Oral contraceptives and endometrial carcinoma: Case for progesterone-receptor defect.
D000230:Adenocarcinoma / Q000139:chemically induced*; D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D003593:Cytoplasm / Q000378:metabolism; D004338:Drug Combinations; D004717:Endometrium / Q000473:pathology; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008535:Megestrol / Q000009:adverse effects / Q000031:analogs & derivatives; D009640:Norethindrone / Q000009:adverse effects; D011980:Receptors, Progesterone; D014594:Uterine Neoplasms / Q000139:chemically induced*
D003276:Contraceptives, Oral; D003280:Contraceptives, Oral, Synthetic; D004338:Drug Combinations; D011980:Receptors, Progesterone; D004997:Ethinyl Estradiol; D008535:Megestrol; D009640:Norethindrone